-
Product Insights
Hypersomnia – Drugs In Development, 2023
Global Markets Direct’s, ‘Hypersomnia - Drugs In Development, 2023’, provides an overview of the Hypersomnia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hypersomnia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nivolumab in Angiosarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nivolumab in Angiosarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nivolumab in Angiosarcoma Drug Details: Nivolumab (Opdivo, Opdyta) is a human IgG4...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PRG-2001 in Bone Disorders
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PRG-2001 in Bone Disorders report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PRG-2001 in Bone Disorders Drug Details: PRG-2001 is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Atopic Dermatitis in Atopic Dermatitis (Atopic Eczema)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Atopic Dermatitis in Atopic Dermatitis (Atopic Eczema) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Atopic Dermatitis in Atopic Dermatitis (Atopic Eczema)Drug Details: Small molecule...
-
Thematic Analysis
State of the Biopharmaceutical Industry in 2024 – Thematic Intelligence
Accessing in-depth insights from the ‘State of the Biopharmaceutical Industry’ report will help you in: Examining the current attitudes of business leaders toward the emerging trends impacting the biopharmaceutical industry in the next 12 months. Benchmarking the impact of major themes on the biopharmaceutical industry in 2024, including emerging technologies, regulatory trends, macroeconomic trends, and industry trends. Identifying the most impactful anticipated regulatory approvals and drug launches in the industry in 2024, learning about top-selling drugs (2023 vs 2024), and obtaining...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Bavisant Dihydrochloride in Hypersomnia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Bavisant Dihydrochloride in Hypersomnia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Bavisant Dihydrochloride in Hypersomnia Drug Details:Bavisant dihydrochloride (BEN-2001, JNJ-31001074) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Bremelanotide Acetate in Diabetic Nephropathy
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Bremelanotide Acetate in Diabetic Nephropathy Drug Details: Bremelanotide acetate (Vyleesi) is belongs to class of...
-
Company Insights
AstraZeneca Plc – Digital Transformation Strategies
Astrazeneca Digital Transformation Strategies Report Overview AstraZeneca uses AI-based technologies as a part of its digital transformation strategies. The annual ICT spending of AstraZeneca was estimated at $1 billion in 2023. A major share of this spending is earmarked for acquiring software, ICT services, and hardware from vendors. AstraZeneca Plc (AstraZeneca) is a biopharmaceutical company, which is focused on the discovery, production, and commercialization of a range of prescription drugs. It develops products related to therapy areas such as respiratory,...
-
Company Profile
BenevolentAI Ltd – Company Profile
BenevolentAI Ltd (BenevolentAI) is a drug discovery company. It carries out developing and applying artificial intelligence (AI) to produce new medicines for the treatment of diseases. The company’s drug programs include BEN2293 (atopic dermatitis), BEN8744 (ulcerative colitis), BEN9160 (amyotrophic lateral sclerosis), glioblastoma multiforme, inflammatory bowel disease, CNS diseases, antiviral, nonalcoholic steatohepatitis (NASH), oncology, Parkinson’s disease, chronic kidney disease, idiopathic pulmonary fibrosis and others. BenevolentAI’s platform enables scientists to design and develop new treatments for patients, using a large amount of...
Add to Basket